Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

WPD Pharmaceuticals Inc WPDPF


Primary Symbol: C.WBIO

Industrials Technology
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.


CSE:WBIO - Post by User

WPD Pharmaceuticals Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(16)
•••
Post by etceteraon Apr 29, 2020 9:50am
168 Views
Post# 30965687

WPD receives approval for Annamycin dose escalation

WPD receives approval for Annamycin dose escalation

2020-04-29 07:33 ET - News Release

 

Mr. Mariusz Olejniczak reports

WPD PHARMACEUTICAL'S ANNAMYCIN DRUG APPROVED FOR ACCELERATED EUROPEAN CLINICAL TRIAL

Through its licence partner, Moleculin Biotech Inc., WPD Pharmaceuticals Inc. has been authorized by the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, known as URPL, to accelerate the phase 1 dose escalation portion of its clinical trial of Annamycin for the treatment of acute myeloid leukemia (AML).

https://www.stockwatch.com/News/Item?bid=Z-C%3aWBIO-2897150&symbol=WBIO&region=C
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities